Eating a high fat and high sugar diet when pregnant leads to metabolic impairments in both the mother and her unborn child, which may 'program' them for potential health complications later in life, a study in mice has shown.
Researchers at the University of Cambridge have taken the first step towards developing a new form of treatment for type 1 diabetes which, if successful, could mean an end to the regular insulin injections endured by people affected by the disease, many of whom are children.
The process by which a mother’s diet during pregnancy can permanently affect her offspring’s attributes, such as weight, could be strongly influenced by genetic variation in an unexpected part of the genome, according to research published today. The discovery could shed light on why many human genetic studies have previously not been able to fully explain how certain diseases, such as type 2 diabetes and obesity, are inherited.
A chemical found in our breath could provide a flag to warn of dangerously-low blood sugar levels in patients with type 1 diabetes, according to new research from the University of Cambridge. The finding, published in the journal Diabetes Care, could explain why some dogs can be trained to spot the warning signs in patients.
An approach that could reduce the chances of drugs failing during the later stages of clinical trials has been demonstrated by a collaboration between the University of Cambridge and pharmaceutical company GlaxoSmithKline (GSK).
The babies of obese women who develop gestational diabetes are five times as likely to be excessively large by six months of pregnancy, according to new research led by the University of Cambridge. The study, which shows that excessive fetal growth begins weeks before at-risk women are screened for gestational diabetes, suggests that current screening programmes may take place too late during pregnancy to prevent lasting health impacts on the offspring.
Graham Ladds, lecturer in pharmacology, discusses the controversy around a group of drugs used to treat Type 2 diabetes.
Scientists have found that some drugs from a group of anti-diabetic treatments may, in certain circumstances, act on glucagon receptors in the body, meaning that they could also potentially enable the release of sugar into the bloodstream.
Technology assisting people with type 1 diabetes edges closer to perfection.
Life expectancy for people with a history of both cardiovascular disease and diabetes is substantially lower than for people with just one condition or no disease, a new study harnessing the power of ‘big data’ has concluded.